- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00663091
A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers (WPP-201)
September 6, 2011 updated by: Randall Wolcott, Southwest Regional Wound Care Center
A Prospective, Randomized Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers
To test safety and efficacy of Bacteriophage on Venous Leg Ulcers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, randomized, controlled double blind study in patients with full thickness venous leg ulcers of greater than 30 days duration evaluating the safety of WPP-201 on the healing of those wounds.
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79410
- Southweast Regional Wound Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must have evidence of hemosiderosis, stasis dermatitis, or dermato liposclerosis; AND edema in the lower extremity on which the wound is present.
- Subject must be at least 18 years of age.
- Subject must have a minimum life expectancy of at least 1 year to be determined by the Investigator.
- The post-debridement ulcer at Day 0 must be free of all necrotic tissue and undermining.
- The study ulcer must be from 1 cm2 to 60 cm2 in size.
- The study ulcer must have been present for greater than 30 days at study Day -7.
- The study ulcer is separated at least 4 cm from all other ulcers at Study Day -7 and Study Day 0 and has a margin of intact skin sufficient for anchoring of the required study dressings.
- The subjects' Glycosylated hemoglobin (HbA1C) must be equal to or less than 10.0% for subjects with diagnosed diabetes at study Day 0.
- The subject, legal guardian or authorized representative must have understood, signed and dated the IRB approved informed consent form.
- The subject must be available for evaluation on a weekly basis for the twelve (12) weeks of the study. Visits at Week 13 and Week 14 are required for initial wound healing, which is achieved in study Week 11 or 12. The Investigator will evaluate both groups at Week 16 and Month 6. Subjects must be available for evaluation at Week 16 and Month 6.
- Subjects' TCpO2 must be equal to or greater than 20 mm of mercury and ABI greater than 0.7.
Exclusion Criteria:
- Subject whose ulcer has healed 30% or greater from the evaluation Study day -7 to the post-debridement Study Day 0 as determined by wound tracings using VisitrakTM.
- A history of alcohol or substance abuse, within the previous year, which could, or in the judgment of the Investigator, would interfere with study compliance or protocol requirements.
- Participation in clinical trials evaluating investigational pharmaceuticals or biologics within 3 months or devices within 30 days of admission to the study.
- Subject with a history of receiving any of the following within the last 30 days: systemic corticosteroids exceeding a total daily dose of 20mg, immunosuppressive agents, radiation therapy or chemotherapy. Anticipated use of the above during the study period will also exclude a subject from entry into the study. Topical and inhaled corticosteroids are not prohibited.
Subject will be excluded if:
- Serum sodium is less than 130 or greater than 147
- Potassium is greater than 5.4 or less than 3.3
- Glucose is less than 55
- Blood urea nitrogen is greater than 31
- Creatinine is greater than 2.1
- Calcium is less than 7
- CPK is greater than 3 times upper limits of normal
- Albumin is less than 2.5
- Total protein is less than 5
- Alkaline phosphatase is greater than 3 times upper limits of normal
- ALT/AST is greater than 5 times upper limits of normal
- Hemoglobin is less than 8
- White blood count is greater than 20,000 or below 1,000
- Subject who is pregnant, lactating or has a positive serum hCG as determined by laboratory testing is excluded from the study.
- Subject who demonstrates allergies to any component in WPP-201 (phage or saline).
- Subject who has previously received any application of bacteriophage.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bacteriophages
|
WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages ("component bacteriophages" or "component phages") lytic for P. aeruginosa, S. aureus, and E. coli (Table 1).
The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages.
The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass.
All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural).
WPP-201 contains no preservatives and antioxidants.
Other Names:
WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages ("component bacteriophages" or "component phages") lytic for P. aeruginosa, S. aureus, and E. coli (Table 1).
The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages.
The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass.
All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural).
WPP-201 contains no preservatives and antioxidants.
Other Names:
WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages ("component bacteriophages" or "component phages") lytic for P. aeruginosa, S. aureus, and E. coli (Table 1).
The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages.
The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass.
All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural).
WPP-201 contains no preservatives and antioxidants.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary objective of this Phase 1 study is to evaluate the safety of the use of WPP-201.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
May 1, 2008
Study Completion (Actual)
May 1, 2008
Study Registration Dates
First Submitted
April 18, 2008
First Submitted That Met QC Criteria
April 21, 2008
First Posted (Estimate)
April 22, 2008
Study Record Updates
Last Update Posted (Estimate)
September 7, 2011
Last Update Submitted That Met QC Criteria
September 6, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 56-RW-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcers
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
HealthpointCompletedVenous Leg Ulcer | Venous Stasis UlcersUnited States, Canada
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Oneness Biotech Co., Ltd.Taipei Veterans General Hospital, Taiwan; Taipei Medical University Shuang...RecruitingVenous Leg Ulcers (VLU)Taiwan
-
University of TurkuUnknown
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Macrocure Ltd.UnknownChronic Venous Leg UlcersUnited States
Clinical Trials on Bacteriophage
-
Tashkent Pediatric Medical InstituteActive, not recruiting
-
Institute of Immunology and Experimental Therapy...Unknown
-
BiomX, Inc.Active, not recruitingCystic Fibrosis | Chronic Pseudomonas Aeruginosa InfectionUnited States, Israel, Spain, Czechia, Netherlands
-
Centre Hospitalier Universitaire de NīmesPherecydes PharmaNot yet recruitingDiabetic Foot | Staphylococcal InfectionsFrance
-
Intralytix, Inc.Johns Hopkins University; Icahn School of Medicine at Mount SinaiRecruiting
-
University of South FloridaUnknownPrimary Immune Deficiency DiseasesUnited States
-
Queen Astrid Military HospitalCompletedBacterial Infections
-
Colorado State UniversityMetabiomics Corp; George Mason UniversityCompletedGastrointestinal Disorder, Functional
-
National Institute of Allergy and Infectious Diseases...CompletedImmunoproliferative DisorderUnited States
-
Adaptive Phage Therapeutics, Inc.United States Department of DefenseTerminatedUrinary Tract Infection BacterialUnited States